512 related articles for article (PubMed ID: 30009772)
1. Different roles of FAT10, FOXO1, and ADRA2A in hepatocellular carcinoma tumorigenesis in patients with alcoholic steatohepatitis (ASH) vs non-alcoholic steatohepatitis (NASH).
Jia Y; French B; Tillman B; French S
Exp Mol Pathol; 2018 Aug; 105(1):144-149. PubMed ID: 30009772
[TBL] [Abstract][Full Text] [Related]
2. The different expression of tumor suppressors, RASSF1A, RUNX3, and GSTP1, in patients with alcoholic steatohepatitis (ASH) vs non-alcoholic steatohepatitis (NASH).
Jia Y; Ji P; French B; Tillman B; French SW
Exp Mol Pathol; 2019 Jun; 108():156-163. PubMed ID: 30951700
[TBL] [Abstract][Full Text] [Related]
3. Alcoholic hepatitis versus non-alcoholic steatohepatitis: Levels of expression of some proteins involved in tumorigenesis.
Nguyen L; Masouminia M; Mendoza A; Samadzadeh S; Tillman B; Morgan T; French B; French S
Exp Mol Pathol; 2018 Feb; 104(1):45-49. PubMed ID: 29307797
[TBL] [Abstract][Full Text] [Related]
4. Comparisons between non-alcoholic steatohepatitis and alcohol-related hepatocellular carcinoma.
Kumar R; Goh BG; Kam JW; Chang PE; Tan CK
Clin Mol Hepatol; 2020 Apr; 26(2):196-208. PubMed ID: 31914720
[TBL] [Abstract][Full Text] [Related]
5. Steatohepatitic Variant of Hepatocellular Carcinoma Is Associated With Both Alcoholic Steatohepatitis and Nonalcoholic Steatohepatitis: A Study of 2 Cohorts With Molecular Insights.
Qin J; Higashi T; Nakagawa S; Fujiwara N; Yamashita YI; Beppu T; Baba H; Kobayashi M; Kumada H; Gunasekaran G; Schiano TD; Thung SN; Fiel MI; Hoshida Y; Ward SC
Am J Surg Pathol; 2020 Oct; 44(10):1406-1412. PubMed ID: 32618599
[TBL] [Abstract][Full Text] [Related]
6. Hepatocellular carcinoma and non-alcoholic steatohepatitis: The state of play.
Charrez B; Qiao L; Hebbard L
World J Gastroenterol; 2016 Feb; 22(8):2494-502. PubMed ID: 26937137
[TBL] [Abstract][Full Text] [Related]
7. Nonalcoholic fatty liver disease and hepatocellular carcinoma.
Zoller H; Tilg H
Metabolism; 2016 Aug; 65(8):1151-60. PubMed ID: 26907206
[TBL] [Abstract][Full Text] [Related]
8. Levels of metacaspase1 and chaperones related to protein quality control in alcoholic and nonalcoholic steatohepatitis.
Mendoza AS; Dorce J; Peng Y; French BA; Tillman B; Li J; French SW
Exp Mol Pathol; 2015 Feb; 98(1):65-72. PubMed ID: 25526666
[TBL] [Abstract][Full Text] [Related]
9. Non alcoholic steatohepatitis a precursor for hepatocellular carcinoma development.
Jiang CM; Pu CW; Hou YH; Chen Z; Alanazy M; Hebbard L
World J Gastroenterol; 2014 Nov; 20(44):16464-73. PubMed ID: 25469014
[TBL] [Abstract][Full Text] [Related]
10. Hepatocellular carcinoma development in non-alcoholic fatty liver disease and non-alcoholic steatohepatitis. Is it going to be the "Plague" of the 21st century? A literature review focusing on pathogenesis, prevention and treatment.
Argyrou C; Moris D; Vernadakis S
J BUON; 2017; 22(1):6-20. PubMed ID: 28365930
[TBL] [Abstract][Full Text] [Related]
11. The SGLT2 Inhibitor Canagliflozin Prevents Carcinogenesis in a Mouse Model of Diabetes and Non-Alcoholic Steatohepatitis-Related Hepatocarcinogenesis: Association with SGLT2 Expression in Hepatocellular Carcinoma.
Jojima T; Wakamatsu S; Kase M; Iijima T; Maejima Y; Shimomura K; Kogai T; Tomaru T; Usui I; Aso Y
Int J Mol Sci; 2019 Oct; 20(20):. PubMed ID: 31652578
[TBL] [Abstract][Full Text] [Related]
12. Preclinical Models for Studying NASH-Driven HCC: How Useful Are They?
Febbraio MA; Reibe S; Shalapour S; Ooi GJ; Watt MJ; Karin M
Cell Metab; 2019 Jan; 29(1):18-26. PubMed ID: 30449681
[TBL] [Abstract][Full Text] [Related]
13. Molecular Pathogenesis of Nonalcoholic Steatohepatitis- (NASH-) Related Hepatocellular Carcinoma.
Kutlu O; Kaleli HN; Ozer E
Can J Gastroenterol Hepatol; 2018; 2018():8543763. PubMed ID: 30228976
[TBL] [Abstract][Full Text] [Related]
14. Identification of chromatin-accessible domains in non-alcoholic steatohepatitis-derived hepatocellular carcinoma.
Dechassa ML; Tryndyak V; de Conti A; Xiao W; Beland FA; Pogribny IP
Mol Carcinog; 2018 Aug; 57(8):978-987. PubMed ID: 29603380
[TBL] [Abstract][Full Text] [Related]
15. Expression of proteins upregulated in hepatocellular carcinoma in patients with alcoholic hepatitis (AH) compared to non-alcoholic steatohepatitis (NASH): An immunohistochemical analysis of candidate proteins.
Lu JG; Nguyen L; Samadzadeh S; Masouminia M; Mendoza A; Sweeney O; Tillman B; Afifyan N; Morgan T; French BA; French SW
Exp Mol Pathol; 2018 Apr; 104(2):125-129. PubMed ID: 29425759
[TBL] [Abstract][Full Text] [Related]
16. Non-alcoholic fatty liver disease associated with hepatocellular carcinoma: An increasing concern.
Dhamija E; Paul SB; Kedia S
Indian J Med Res; 2019 Jan; 149(1):9-17. PubMed ID: 31115369
[TBL] [Abstract][Full Text] [Related]
17. Post-transplantation outcome in non-alcoholic steatohepatitis cirrhosis: Comparison with alcoholic cirrhosis.
Castelló B; Aguilera V; Blázquez MT; Rubín Á; García M; Vinaixa C; Benlloch S; SanJuan F; Montalva E; López R; Berenguer M
Ann Hepatol; 2019; 18(6):855-861. PubMed ID: 31543468
[TBL] [Abstract][Full Text] [Related]
18. Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis and Hepatocellular Carcinoma.
Massoud O; Charlton M
Clin Liver Dis; 2018 Feb; 22(1):201-211. PubMed ID: 29128057
[TBL] [Abstract][Full Text] [Related]
19. Activation of apoptosis inhibitor of macrophage is a sensitive diagnostic marker for NASH-associated hepatocellular carcinoma.
Koyama N; Yamazaki T; Kanetsuki Y; Hirota J; Asai T; Mitsumoto Y; Mizuno M; Shima T; Kanbara Y; Arai S; Miyazaki T; Okanoue T
J Gastroenterol; 2018 Jun; 53(6):770-779. PubMed ID: 29086016
[TBL] [Abstract][Full Text] [Related]
20. Systematic review with meta-analysis: risk of hepatocellular carcinoma in non-alcoholic steatohepatitis without cirrhosis compared to other liver diseases.
Stine JG; Wentworth BJ; Zimmet A; Rinella ME; Loomba R; Caldwell SH; Argo CK
Aliment Pharmacol Ther; 2018 Oct; 48(7):696-703. PubMed ID: 30136293
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
